Suppliers / Seacross Pharma (Europe)

Seacross Pharma (Europe)

United Kingdom 30 employees Updated 9 July 2026

Seacross Pharma (Europe) is an API and finished-dose manufacturer based in United Kingdom. It holds 3 active US drug master files across a filed portfolio of 3 molecules. Its filings concentrate with EMA, FAMHP (BE) and MHRA (UK). Its GMP standing is certified by MHRA (UK) and EMA.

3
active US DMFs
0
valid CEPs
5
registered plants
377
filings across 14 regulators
These figures were checked against the regulators' own files on 25 July 2026
EU GMP
1 of 1 confirmed
Sources: EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Registered plants

Site FDA FEI
London, United Arab Emirates Not on file
Stanmore HA7 1BT, United Arab Emirates Not on file
LONDON, United Kingdom Not on file
Blackrock, Ireland Not on file
Vialonga, Portugal Not on file

What they file, and where

Molecule Regulators Docs
Bortezomib US FDA 1
Leucovorin Calcium US FDA 1
Thiotepa US FDA 1

Also appears on these molecule pages

Azacitidine finished dose Bendamustine finished dose Bortezomib API Cisatracurium finished dose Decitabine finished dose Leucovorin API Paclitaxel finished dose Pemetrexed Disodium finished dose Plerixafor finished dose Sodium Valproate finished dose Teicoplanin finished dose Thiotepa API

Filings and GMP by regulator

Regulator Filings GMP certificates
EMA 111 1
FAMHP (BE) 104 None
MHRA (UK) 90 2
AIFA (IT) 16 None
INFARMED (PT) 14 None
EDE (AE) 13 None

Comparing suppliers?

Choose your molecules and target markets. Seacross Pharma (Europe) comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates